No biomarker	Oral Cancer	No biomarker	Oral Cancer	5-fluorouracil + hydroxyurea Sensitive: A2 - Guideline 5-fluorouracil + hydroxyurea Sensitive : A2	5-fluorouracil + hydroxyurea Sensitive: A2 - Guideline 5-fluorouracil + hydroxyurea Sensitive : A2
No biomarker	Oropharyngeal Cancer	No biomarker	Oropharyngeal Cancer	5-fluorouracil + hydroxyurea Sensitive: A2 - Guideline 5-fluorouracil + hydroxyurea Sensitive : A2	5-fluorouracil + hydroxyurea Sensitive: A2 - Guideline 5-fluorouracil + hydroxyurea Sensitive : A2
FLT3-ITD mutation + PML-RARA fusion + WT1 overexpression	Acute Promyelocytic Leukemia	FLT3-ITD mutation + PML-RARA fusion + WT1 overexpression	Acute Promyelocytic Leukemia	cytarabine + idarubicin hydrochloride + arsenic trioxide + hydroxyurea Sensitive: C4 – Case Studies cytarabine + idarubicin hydrochloride + arsenic trioxide + hydroxyurea Sensitive : C4	cytarabine + idarubicin hydrochloride + arsenic trioxide + hydroxyurea Sensitive: C4 – Case Studies cytarabine + idarubicin hydrochloride + arsenic trioxide + hydroxyurea Sensitive : C4
TP53 mutation	Triple Negative Breast Cancer	TP53 mutation	Triple Negative Breast Cancer	NSC-324360 Sensitive: D – Preclinical NSC-324360 Sensitive : D	NSC-324360 Sensitive: D – Preclinical NSC-324360 Sensitive : D
BRCA wild-type	Ovarian Cancer	BRCA wild-type	Ovarian Cancer	olaparib + cediranib + 3-AP Sensitive: D – Preclinical olaparib + cediranib + 3-AP Sensitive : D	olaparib + cediranib + 3-AP Sensitive: D – Preclinical olaparib + cediranib + 3-AP Sensitive : D

Ribonucleotide reductase inhibitor

Ribonucleotide reductase inhibitor

Associations(5)

Associations
(5)